Harrow announced leadership changes at its wholly owned subsidiary, ImprimisRx. Frank Mullery has been appointed as CEO and Bridseida Cruz has been appointed as head of quality of ImprimisRx.

Mullery is a senior executive with more than 20 years of leadership experience in the health care and pharmaceutical industries. Most recently, he served as president of Sintetica US, where he spearheaded the creation of the company’s US subsidiary. Previously, he served as president and chief commercial officer of STI Pharma, where he oversaw all company operations, including launching several sterile injectable products.

Cruz is an executive with more than 25 years of experience leading quality and operations in 503B outsourcing, pharmaceutical, and medical device organizations. Her notable achievements include leading the US Food and Drug Administration (FDA) Warning Letter and regulatory observation remediation plans. She has also successfully commissioned and launched a new FDA-registered compounding facility.